Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration

Eye (Basingstoke)

Volumn 29, Issue 7, 2015, Pages 902-912

  Akuffo, K O ^a   Nolan, J M ^a   Howard, A N ^b   Moran, R ^a   Stack, J ^a   Klein, R ^c   Klein, B E ^c   Meuer, S M ^c   Sabour Pickett, S ^a   Thurnham, D I ^d   Beatty, S ^a  

^a South East Technological University   (Ireland)

^b Howard Foundation   (United Kingdom)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAROTENOID; MESO ZEAXANTHIN; UNCLASSIFIED DRUG; VISUAL PIGMENT; XANTHOPHYLL; ZEAXANTHIN; MESO-ZEAXANTHIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BEST CORRECTED VISUAL ACUITY; CHEMICAL COMPOSITION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CUSTOMIZED HETEROCHROMATIC FLICKER PHOTOMETRY; DISEASE COURSE; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DRUG BLOOD LEVEL; DRUG FORMULATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PHOTOMETRY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION; VITAMIN SUPPLEMENTATION; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DIETARY SUPPLEMENT; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACULAR DEGENERATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADMINISTRATION, ORAL; CAROTENOIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST SENSITIVITY; DIETARY SUPPLEMENTS; DRUG COMPOUNDING; HUMANS; LUTEIN; MACULAR DEGENERATION; MACULAR PIGMENT; PHOTOMETRY; SINGLE-BLIND METHOD; VISUAL ACUITY; ZEAXANTHINS;

EID: 84949189374     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2015.64     Document Type: Article

References (30)

1. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-374
2. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001; 385: 28-40
3. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38: 1802-1811
4. Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao DY, Katz NB. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res 2001; 72: 215-223
5. Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S. Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment. Exp Eye Res 2012; 101: 9-15
6. Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci 2012; 53(12): 7871-7880
7. Nolan JM, Loskutova E, Howard AN, Moran R, Mulcahy R, Stack J, et al. Macular pigment, visual function, and macular disease among subjects with Alzheimer's disease: an exploratory study. J Alzheimers Dis 2014; 42(4): 1191-1202
8. Sabour-Pickett S, Beatty S, Connolly E, Loughman J, Stack J, Howard A, et al. Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration. Retina 2014; 34(9): 1757-1766
9. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, et al. The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123: 1484-1498
10. Meagher KA, Thurnham DI, Beatty S, Howard AN, Connolly E, Cummins W, et al. Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. Br J Nutr 2013; 110: 289-300
11. Nolan JM, Meagher K, Kashani S, Beatty S. What is meso-zeaxanthin, and where does it come from?. Eye (Lond) 2013; 27: 899-905
12. Wooten BR, Hammond BR, Land RI, Snodderly DM. A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 1999; 40: 2481-2489
13. Thurnham DI, Tremel A, Howard AN. A supplementation study in human subjects with a combination of mesozeaxanthin, (3R, 3′R)-zeaxanthin and (3R, 3′R, 6′R)-lutein. Br J Nutr 2008; 100: 1307-1314
14. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991; 98: 1128-1134
15. Sparrow JM, Dickinson AJ, Duke AM. The Wisconsin Agerelated Macular Degeneration grading system: performance in an independent centre. Ophthalmic Epidemiol 1997; 4: 49-55
16. O'Neill ME, Carroll Y, Corridan B, Olmedilla B, Granado F, Blanco I, et al. A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. Br J Nutr 2001; 85: 499-507
17. O'Connell ED, Nolan JM, Stack J, Greenberg D, Kyle J, Maddock L, et al. Diet and risk factors for age-related maculopathy. Am J Clin Nutr 2008; 87: 712-722
18. Johnson EJ, Neuringer M, Russell RM, Schalch W, Snodderly DM. Nutritional manipulation of primate retinas, III: effects of lutein or zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys. Invest Ophthalmol Vis Sci 2005; 46: 692-702
19. Bhosale P, Zhao DY, Serban B, Bernstein PS. Identification of 3-methoxyzeaxanthin as a novel age-related carotenoid metabolite in the human macula. Invest Ophthalmol Vis Sci 2007; 48: 1435-1440
20. Loane E, Nolan JM, O'Donovan O, Bhosale P, Bernstein PS, Beatty S. Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular degeneration. Surv Ophthalmol 2008; 53: 68-81
21. Murray IJ, Makridaki M, van Der Veen RL, Carden D, Parry NR, Berendschot TT. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Invest Ophthalmol Vis Sci 2013; 54: 1781-1788
22. Beatty S, Nolan JM, Muldrew KA, Woodside J, Stevenson MR, Chakravarthy U. Visual outcome after antioxidant supplementation. Ophthalmology 2013; 120: 645
23. Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Woodside JV, Denny F, et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology 2013; 120: 600-606
24. Charalampidou S, Loughman J, Nolan J, Stack J, Cassidy L, Pesudovs K, et al. Prognostic indicators and outcome measures for surgical removal of symptomatic nonadvanced cataract. Arch Ophthalmol 2011; 129(9): 1155-1161
25. Kleiner RC, Enger C, Alexander MF, Fine SL. Contrast sensitivity in age-related macular degeneration. Arch Ophthalmol 1988; 106: 55-57
26. Pelli DG, Bex P. Measuring contrast sensitivity. Vision Res 2013; 90: 10-14
27. Garcia-Layana A, Recalde S, Alaman AS, Robredo PF. Effects of lutein and docosahexaenoic acid supplementation on macular pigment optical density in a randomized controlled trial. Nutrients 2013; 5: 543-551
28. Akuffo KO, Beatty S, Stack J, Dennison J, O'Regan S, Meagher KA, et al. Central Retinal Enrichment Supplementation Trials (CREST): Design and Methodology of the CREST Randomized Controlled Trials. Ophthalmic Epidemiol 2014; 21: 111-123
29. Age Related Eye Disease Study 2 Research Group. Lutein +zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015
30. Chew EY, Clemons TE, SanGiovanni JP, Danis RP, Ferris FL III, Elman MJ, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 Report No. 3. JAMA Ophthalmol 2014; 132(2): 142-149